Effects of Arctium lappa L. Root Powder on Some Markers of Oxidative Stress and Inflammation in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind Controlled Clinical Trial Study
Abstract
Objective: Polycystic ovary syndrome (PCOS) is one of the most prevalent disorders of the endocrine system, with significant implications for female fertility. Antioxidant supplementation may contribute to its better management. This study aimed to investigate the effects of Arctium lappa L. root powder as an antioxidant on some markers of oxidative stress and inflammation, ovary volume, hirsutism score, and menstrual frequency in women with polycystic ovary syndrome.
Methods: This randomized, double-blind, controlled clinical trial was conducted in 2023-2024 at Arak University of Medical Sciences. Sixty subjects with polycystic ovary syndrome were selected by convenience sampling method and allocated to Arctium lappa L. (n=30) and placebo (n=30) by permuted block randomization method and then treated with Arctium lappa L. root powder (460 mg/day) or placebo (460 mg/day) for 12 weeks. Before and after the intervention, some markers of oxidative stress and inflammation, ovary volume, hirsutism score, and menstrual frequency were measured and compared between the two groups.
Results: The values of antioxidative markers, such as superoxide dismutase and catalase, increased significantly (p<0.001). Furthermore, values of oxidative and inflammation markers such as malondialdehyde and C-reactive protein decreased significantly (p<0.001) in the Arctium lappa L. compared to the placebo group. Moreover, the volume of the right and left ovaries was also reduced significantly (p=0.02,…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 30 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.